6-(3,5-difluorophenyl)-2-(5'-methyl-[2,2']bipyridinyl-6-yl-methyl)-2H-pyridazin-3-one | 1192224-44-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-(3,5-difluorophenyl)-2-(5'-methyl-[2,2']bipyridinyl-6-yl-methyl)-2H-pyridazin-3-one
• 英文别名: 6-(3,5-Difluorophenyl)-2-[[6-(5-methylpyridin-2-yl)pyridin-2-yl]methyl]pyridazin-3-one
• CAS: 1192224-44-4
• 化学式: C₂₂H₁₆F₂N₄O
• 分子量: 390.392
• InChiKey: ULFXBCUALMOTLA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  58.4
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  5-methylpyridine-2-boronic acid N-phenyldiethanolamine ester 、 2-(6-bromopyridin-2-ylmethyl)-6-(3,5-difluorophenyl)-2H-pyridazin-3-one 在 bis-triphenylphosphine-palladium(II) chloride potassium phosphate monohydrate 、 三乙胺 作用下， 以 乙二醇二甲醚 为溶剂， 生成 6-(3,5-difluorophenyl)-2-(5'-methyl-[2,2']bipyridinyl-6-yl-methyl)-2H-pyridazin-3-one
  参考文献：
  名称：

  PYRIDAZINONE DERIVATIVES

  摘要：

  式(I)的化合物，其中R1、R2、R3、W和D具有权利要求1所示的含义，是酪氨酸激酶的抑制剂，特别是Met激酶的抑制剂，可用于治疗肿瘤等疾病。

  公开号：

  US20110034474A1

文献信息

• PYRIDAZINONDERIVATE
  申请人：Merck Patent GmbH

  公开号：EP2280962A1

  公开（公告）日：2011-02-09
• COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS
  申请人：BROWN Dennis M.

  公开号：US20160067241A1

  公开（公告）日：2016-03-10

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to naphthalimides such as amonafide or analogs, derivatives, or prodrugs thereof.
• US8604036B2
  申请人：——

  公开号：US8604036B2

  公开（公告）日：2013-12-10
• [DE] PYRIDAZINONDERIVATE<br/>[EN] PYRIDAZINONE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRIDAZINONES
  申请人：MERCK PATENT GMBH

  公开号：WO2009129905A1

  公开（公告）日：2009-10-29

  Verbindungen der Formel (I) worin R1, R2, R3, W und D die in Anspruch 1 angegebenen Bedeutungen haben, sind Inhibitoren der Tyrosinkinasen, insbesondere der Met-Kinase und können u.a. zur Behandlung von Tumoren eingesetzt werden.
• [EN] COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS<br/>[FR] COMPOSITIONS ET PROCÉDÉS PERMETTANT D'AMÉLIORER LE BÉNÉFICE THÉRAPEUTIQUE DES COMPOSÉS CHIMIQUES ADMINISTRÉS DE MANIÈRE SUBOPTIMALE COMPRENANT DES NAPHTALIMIDES SUBSTITUÉS TELS QUE L'AMONAFIDE POUR LE TRAITEMENT DES MALADIES IMMUNOLOGIQUES, MÉTABOLIQUES, INFECTIEUSES ET INFECTIEUSES OU HYPERPROLIFÉRATIVES ET NÉOPLASTIQUES.
  申请人：BROWN DENNIS M

  公开号：WO2014179528A2

  公开（公告）日：2014-11-06

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to naphthalimides such as amonafide or analogs, derivatives, or prodrugs thereof.